Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eprenetapopt. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eprenetapopt SCHEMBL21636035 | 1.00 | MEN1 (0.72) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| Eprenetapopt SCHEMBL27272034 | 1.00 | MEN1 (0.72) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| Eprenetapopt SCHEMBL2228161 | 1.00 | MEN1 (0.72) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL29965401 | 0.94 | MEN1 (0.64) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL29965910 | 0.94 | MEN1 (0.64) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL29965601 | 0.94 | MEN1 (0.64) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL29965376 | 0.94 | MEN1 (0.64) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| Eprenetapopt SCHEMBL28990156 | 0.92 | MEN1 (0.60) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL30382084 | 0.91 | MEN1 (0.58) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL23727096 | 0.91 | MEN1 (0.58) | MEN1MAPTCYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217964-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217964-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. | 2024-07-04 | — | — | US | disclosed |
| CN-116034107-A | Quinuclidinone analogs as anticancer agents | 新波制药有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20230089530-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. | 2023-03-23 | — | — | US | disclosed |
| EP-4100407-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | Newave Pharmaceutical Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022204109-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2021158948-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089530-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NQO2, CNKSR1, NQO1 | MEN1 130/4885MAPT 4494/4885CYP2C9 3910/4885 |
| US-20240217964-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NQO2, PRMT1, PRMT7 | MEN1 400/4885MAPT 4095/4885CYP2C9 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.